News articles about iCo Therapeutics (OTCMKTS:ICOTF) have been trending somewhat negative on Tuesday, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than 6,000 blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. iCo Therapeutics earned a media sentiment score of -1.07 on their scale. InfoTrie also assigned media coverage about the biotechnology company an news buzz score of 10 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company’s share price in the next several days.
iCo Therapeutics stock remained flat at $$0.05 during midday trading on Tuesday. 3,000 shares of the company were exchanged, compared to its average volume of 4,725. iCo Therapeutics has a 1 year low of $0.02 and a 1 year high of $0.20.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/12/04/ico-therapeutics-icotf-earning-somewhat-critical-news-coverage-analysis-finds.html.
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
Further Reading: Determine Your Level of Risk Tolerance
Receive News & Ratings for iCo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.